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use and costs were obtained from 5000 randomized hospital records from the Social 
Security Mexican Institute(IMSS) and ofﬁ cial institutional databases. Costs include 
outpatient and inpatient services, drug, procedures, etc. The model was validated 
according to international guidelines. Probabilistic sensitivity analyses were performed 
employing bootstrapping techniques and acceptability curves were constructed. 
RESULTS: The highest percentage of patients with no or mild pain during the follow-
up period was obtained by pregabalin(44.8%; CI95% 42.8%–48.0%); followed 
by gabapentin(38.1%; CI95% 33.2%–43.5%); duloxetine(34.2%; CI95% 27.8%–
40.6%) and amitriptyline(22.2%; CI95% 21.0%–24.0%).The annual expected
mean costs per patient were US$1503.2(US$1472.2–US$1534.09); US$1,742.7
(US$1,715.1–US$1,770.2); US$2,046.6(US$2018.6–US$2074.7) and US$643.6(US$615.2–
US$673.5), respectively. The ICER of pregabalin vs. amitriptyline(basecase) was
US$3798.9(US$3336.1–US$4,325.9). Other treatments were dominated by pregaba-
lin. Second-order Monte Carlo sensitivity analyses indicated that pregabalin would be 
a cost-saving strategy in a range of 60%–70% within accepted thresholds(p  0.05). 
CONCLUSIONS: In Mexico, pregabalin showed to be a cost-effective and cost-saving 
therapy when compared with amitriptyline and other usual treatments in the manage-
ment of FM.
PSY22
ECONOMIC EVALUATION OF RECOMBINANT FACTOR VIII PRODUCTS
IN TREATMENT OF HAEMOPHILIA A. IN KOREA
Kim JY1, Lee JH2, Heo JH1, Lee EK1
1Sook Myung Women’s University, Seoul, South Korea, 2Sook Myung Women’s University, 
Seoul, Seoul, South Korea
OBJECTIVES: Haemophilia A is a hereditary genetic disorder with a relatively high 
burden of disease from the perspective of both society and the individual patient. 
Kogenate FS is a second-generation full-length recombinant factor VIII (FVIII), pro-
duced without the addition of human albumin during formulation. It shows lower
incidence of inhibitors compared with other recombinant factor VIII products, which 
has an impact on economic evaluation because the haemophilia patients with inhibi-
tors have to be treated with a signiﬁ cantly higher dosage or expensive bypassing
agents. The main objective of this study is to conduct economic evaluation of Kogenate
FS compared with Recombinate in haemophilia A patients in Korea. METHODS: A 
cost-minimization analysis was performed under the assumption that Kogenate FS and 
Recombinate were clinically equivalent for treating bleeding episodes. A decision-
analytic model was developed to estimate the lifetime costs by reﬂ ecting each different 
treatment strategies for haemophilia A patients with inhibitors or not. If patients had
inhibitors, it was ramiﬁ ed according to the inhibitor titres into one of three pathways: 
5BU, 5–10BU, and 10BU. The analysis was conducted based on the societal perspec-
tive, and costs were discounted at 5% annually. Sensitivity analyses were performed
on crucial parameters. RESULTS: Incidence of inhibitor for Kogenate FS and Recom-
binate were 8.113% and 16.9% respectively. Using the base case analysis, the expected 
cost for Kogenate FS was US$1,979,133 compared with $2,382,332 for Recombinate.
So, Kogenate FS is $403,199 lower than Recombinate during lifetime. The differences
were mainly due to the higher inhibitor treatment costs. One-way sensitivity analysis 
revealed stable across included parameters. CONCLUSIONS: This cost minimization
study identiﬁ ed that treatment of Kogenate FS appears to save costs compared with
treatment of Recombinate. By initiating and continuing Kogenate FS treatment, the 
economic burden associated with Haemophilia A can be reduced under Korean health 
care system.
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OBJECTIVES: To perform economical evaluation of darbepoetin alfa vs. epoetin
alfa in hemodialysis patients with anemia and chronic kidney disease. METHODS:
The modeled study was performed. Proportion of patients receiving alternative
eritropoesis-stimulating proteins (ESP) dosing regimen, efﬁ cacy and safety of drugs
were extracted from multicenter randomized study made by Nissenson et al (American 
Journal of Kidney Diseases 2002; 1:110–8). Cost of treatment with ESPs for 28 weeks
and cost-minimization ratio (CMR) were calculated from the Russian reimbursement 
system point of view. RESULTS: According to selected study, the efﬁ cacy and safety
proﬁ le of darbepoetin alfa was similar to that of epoetin alfa. Mean dose decrease 
from 63.18 Mg/wk to 54.18 Mg/wk was observed in darbepoetin alfa group, while mean 
dose increase from 12,706 to 13,639 was registered in epoetin alfa group during 28
weeks. The costs of used medications were the same for darbepoetin alfa and epoetin 
alfa (RUB230,148.1 vs. RUB 229,427.19 (USD7,292.4 vs. USD7,269.56). The cost 
of medical manipulations were less for darbepoetin alfa due to its reduced dosing fre-
quency (RUB2284.8 vs. RUB6854.8 (US$72.4 vs. USD217.2) accordingly). Cost-
minimization analysis showed that cost of treatment with darbepoetin alfa is less then
epoetin alfa (CER  RUB3384.7 (US$107.3)). Sensitivity analysis was made on the 
basis of model, constructed with data extracted from other study (Molina et al.,
Nephrologia 2004; 6). It conﬁ rmed the results of present work. CONCLUSIONS:
According to the model darbepoetin alfa seems to be as effective and safe as epoetin
alfa, but it takes fewer costs for treatment of anemia in hemodialysis patients with
chronic kidney disease due to low dosing frequency and dose saving effect.
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OBJECTIVES: To quantify the effect of obesity on the total direct medical expenditure 
and health related quality of life in the population of the United States. METHODS:
Data from the MEPS’s Household Component (2006), a nationally representative 
survey of the U.S. civilian non-institutionalized population, was used. Analysis
accounted for the survey’s clusters, strata and sampling weights. Obesity was deﬁ ned
as body mass index q30. Direct medical expenditure attributable to obesity was esti-
mated under diverse econometric models to assess sensitivity to zero-mass, non-nega-
tive values and skewed distribution. Models compared were ordinary least-squares
(OLS) on raw and log-transformed expenditures (homoskedastic and heteroskedastic 
re-transformations), and generalized linear models (GLM) with log-link and Gamma/
Poisson families, including 2-part variants of these 5 models. Box-Cox test and Modi-
ﬁ ed Park’s test determined the link and family in the GLM models. LINK, RESET, 
Hosmer-Lemeshow and Pearson’s correlation test determined model ﬁ t, while Copas
test was employed for over-ﬁ tting and cross validation. Incremental expenditure from 
the method of recycled predictions summed over population with obesity gave the 
total expenditure. Impact of obesity on SF12 mental and physical health component 
was assessed by OLS. Covariates included age, gender, race, ethnicity, income, geo-
graphic-location, and comorbidity. RESULTS: The 2-part model of OLS on raw
expenditure was the only model to pass all the speciﬁ cation and cross-validation tests.
Based on this model, annual incremental expenditure of obesity was $1188.50 (95%
CI  $1183.70 to $1193.40). Total direct expenditure of obesity was $72 billion (95%
CI  $68.2 to $75.8 billion), nearly 3-fold increase compared to 1998 estimates. SF12
physical component score was lower by 3.7 (p  0.001) while the mental component
score was lower by 1.2 (p  0.001) for those with obesity. These decrements are similar
to those observed for diabetes or hypertension. CONCLUSIONS: Obesity exerts an 
enormous economic and humanistic burden on the U.S. civilian non-institutionalized
population.
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OBJECTIVES: To estimate the prevalence of asthma with obesity and the annual
medical costs attributable to obesity. METHODS: The cross-sectional analysis 
was conducted from adults aged 18–74 who participated in the 2003–2006 
Medical Expenditure Panel Survey. Total of 6670 asthma patients were identiﬁ ed
based on the self reported diagnosis or ICD-9-CM code of 493 after excluding 
patients with pregnancy, malignancy, kidney dialysis, immunodeﬁ ciency, or body-
mass-index(BMI) 18.5. These patients were classiﬁ ed as normal (BMI:18.5-25) or 
obese(BMI:q30). Total medical costs included ofﬁ ce based physician/outpatient visits, 
emergency room visit, or hospitalization except dental problems and injuries. Costs 
related to respiratory system diseases were costs associated with ICD-9-CM of 460–
516. The medical cost attributable to obesity was the difference between the observed 
cost and the predicted cost which was calculated using the parameters estimated from
obese patients. The parameters for obese patients were estimated using a generalized
linear model with a log link function and a gamma distribution after adjusting for
demographic, social-economic, and co-morbidity variables. All costs were converted 
to 2006 U.S. dollars using price indices. Data were analyzed using SAS/STATA. 
RESULTS: The age-adjusted prevalence of asthma in total population was 8.2% and 
that of asthma with obesity was 2.8% respectively. The average total medical treat-
ment costs in obese asthma patients were $5090 (95%CI:$4639–$5540), signiﬁ cantly 
higher than normal weight patients ($2,825;95%CI:$2291–$3359:p  0.001). After 
adjustments, the total medical costs attributable to obesity per patient were $3,960
(95%CI:$3,693–$4,228). Of that cost, $154 was attributable to respiratory system
diseases (95%CI:$48–$259) with the biggest increment in patients aged 65–74 old. 
CONCLUSIONS: Obesity is prevalent in general population as well as asthma
patients. The average medical cost attributable to obesity was signiﬁ cantly higher than 
normal weight asthma patients. Effective public programs aiming at educating the
importance of controlling weight are strongly recommended to diminish the economic
burden of obesity.
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OBJECTIVES: Although opioids have not demonstrated efﬁ cacy in treating ﬁ bromy-
algia (FM) and pose a risk for addiction, they are commonly used to treat FM patients. 
This study assesses the mean annual per patient cost of FM-related opioid use in 
commercially insured FM patients. METHODS: Using the Thomson/Medstat Mar-
ketScan Commercial Claims Database, we identiﬁ ed all patients aged 18 years with 
continuous health plan eligibility in 2006 and q1 inpatient or q2 outpatient paid 
medical claims in calendar year 2006 with ICD-9-CM diagnosis code 729.1 (“FM
patients”). Rx medications designated as possibly related to FM treatment (“FM-
